105 related articles for article (PubMed ID: 7974375)
41. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Robbie LA; Dummer S; Booth NA; Adey GD; Bennett B
Br J Haematol; 2000 May; 109(2):342-8. PubMed ID: 10848822
[TBL] [Abstract][Full Text] [Related]
42. Thrombin modulates synthesis of plasminogen activator inhibitor type 2 by human peripheral blood monocytes.
Ritchie H; Jamieson A; Booth NA
Blood; 1995 Nov; 86(9):3428-35. PubMed ID: 7579447
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic angiogenesis improves fibrinolytic imbalance in patients with critical limb ischemia.
Chudý P; Chudá D; Ivanková J; Sinák I; Talapková R; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2014 Mar; 25(2):156-60. PubMed ID: 24300022
[TBL] [Abstract][Full Text] [Related]
44. Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis.
Huber K; Kirchheimer JC; Korninger C; Binder BR
Thromb Res; 1991 Jun; 62(5):491-500. PubMed ID: 1910213
[TBL] [Abstract][Full Text] [Related]
45. Formation and persistence of procoagulant and fibrinolytic activities in circulation after strenuous physical exercise.
Hansen JB; Wilsgård L; Olsen JO; Osterud B
Thromb Haemost; 1990 Nov; 64(3):385-9. PubMed ID: 2096490
[TBL] [Abstract][Full Text] [Related]
46. Effects of labor and delivery on fibrinolysis.
Bremer HA; Brommer EJ; Wallenburg HC
Eur J Obstet Gynecol Reprod Biol; 1994 Jun; 55(3):163-8. PubMed ID: 7958159
[TBL] [Abstract][Full Text] [Related]
47. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension.
Olman MA; Marsh JJ; Lang IM; Moser KM; Binder BR; Schleef RR
Circulation; 1992 Oct; 86(4):1241-8. PubMed ID: 1394930
[TBL] [Abstract][Full Text] [Related]
48. Fibrinolytic parameters in children with noncatheter thrombosis: a pilot study.
Kupesiz OA; Chitlur MB; Hollon W; Tosun O; Thomas R; Warrier I; Lusher JM; Rajpurkar M
Blood Coagul Fibrinolysis; 2010 Jun; 21(4):313-9. PubMed ID: 20305541
[TBL] [Abstract][Full Text] [Related]
49. Dietary effects on circadian fluctuation in human blood coagulation factor VII and fibrinolysis.
Marckmann P; Sandström B; Jespersen J
Atherosclerosis; 1993 Jul; 101(2):225-34. PubMed ID: 8397516
[TBL] [Abstract][Full Text] [Related]
50. Differential regulation of tissue factor and plasminogen activator inhibitor by human mononuclear cells.
Schwartz BS; Bradshaw JD
Blood; 1989 Oct; 74(5):1644-50. PubMed ID: 2790190
[TBL] [Abstract][Full Text] [Related]
51. Modulating the fibrinolytic system of peripheral blood mononuclear cells with adenovirus.
Schleef RR; Olman MA; Miles LA; Chuang JL
Hum Gene Ther; 2001 Mar; 12(4):439-45. PubMed ID: 11242535
[TBL] [Abstract][Full Text] [Related]
52. Seminal clotting and fibrinolytic balance: a possible physiological role in the male reproductive system.
Lwaleed BA; Greenfield R; Stewart A; Birch B; Cooper AJ
Thromb Haemost; 2004 Oct; 92(4):752-66. PubMed ID: 15467906
[TBL] [Abstract][Full Text] [Related]
53. Increased release of plasminogen activator inhibitor type 2 accompanies the human mononuclear cell tissue factor response to lipopolysaccharide.
Schwartz BS; Monroe MC; Levin EG
Blood; 1988 Mar; 71(3):734-41. PubMed ID: 3345343
[TBL] [Abstract][Full Text] [Related]
54. Effect of Helicobacter pylori lipopolysaccharide (LPS) and LPS derivatives on the production of tissue factor and plasminogen activator inhibitor type 2 by human blood mononuclear cells.
Semeraro N; Montemurro P; Piccoli C; Muolo V; Colucci M; Giuliani G; Fumarola D; Pece S; Moran AP
J Infect Dis; 1996 Dec; 174(6):1255-60. PubMed ID: 8940216
[TBL] [Abstract][Full Text] [Related]
55. Effect of lipoproteins on tissue factor activity and PAI-II antigen in human monocytes and macrophages.
Wada H; Kaneko T; Wakita Y; Minamikawa K; Nagaya S; Tamaki S; Deguchi K; Shirakawa S
Int J Cardiol; 1994 Dec; 47(1 Suppl):S21-5. PubMed ID: 7737748
[TBL] [Abstract][Full Text] [Related]
56. Effect of endurance training and seasonal fluctuation on coagulation and fibrinolysis in young sedentary men.
van den Burg PJ; Hospers JE; van Vliet M; Mosterd WL; Bouma BN; Huisveld IA
J Appl Physiol (1985); 1997 Feb; 82(2):613-20. PubMed ID: 9049745
[TBL] [Abstract][Full Text] [Related]
57. [Dynamic changes and significance of antithrombin and fibrinolytic function in advanced lung cancer patients during chemotherapy].
Wang M; Yang L; Pan J; Wang X; Lu H; Lu M; Chen S; Xie Y
Zhongguo Fei Ai Za Zhi; 2007 Jun; 10(3):226-8. PubMed ID: 21118652
[TBL] [Abstract][Full Text] [Related]
58. Arginine506 to glutamin mutation in the factor V gene in infancy and childhood: evidence of fibrinolytic impairment.
Nowak-Göttl U; Vielhaber H; Grohmann J; Schneppenheim R; Koch HG
Eur J Pediatr; 1997 Mar; 156(3):195-8. PubMed ID: 9083758
[TBL] [Abstract][Full Text] [Related]
59. Regulation of tissue plasminogen activator in sickle cell anemia.
Phillips G; Hartman J; Keller VA; Santiago MA; Pizzo S
Am J Hematol; 1990 Nov; 35(3):167-70. PubMed ID: 2121022
[TBL] [Abstract][Full Text] [Related]
60. Urinary procoagulant and fibrinolytic activity in human glomerulonephritis. Relationship with renal function.
Colucci M; Semeraro N; Montemurro P; Chiumarulo P; Triggiani R; Morrone LF; Schena FP
Kidney Int; 1991 Jun; 39(6):1213-7. PubMed ID: 1910125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
